India, Nov. 13 -- The commercial biotechnology company Allergy Therapeutics Inc. (AGY.L) released on Friday preliminary financial results for the fiscal year ended on June 30, 2026. The company noted a wider loss before tax owing to increased expenditures.
Allergy Therapeutics is focused on the diagnosis and treatment of allergic disorders with aluminum-free therapies. The company provides medications in nine different European markets and is additionally advancing therapies to battle dust mite allergies and anaphylaxis due to peanut allergy.
FY2026 Financial Results:
Loss before tax expanded to £50.06 million in the full fiscal year of 2026, relatively higher than the £39.20 million reported for the full year of 2025.
The inc...